ARCH Venture Partners

Kardigan is a pioneering heart health company dedicated to transforming cardiovascular drug development. It focuses on identifying and matching critical disease drivers with responsive patients from clinical trials, aiming to deliver curative medicines that go beyond symptom management, ultimately providing functional cures for cardiovascular diseases.

Rhygaze is a biotechnology company focused on developing innovative gene therapies aimed at restoring vision in individuals affected by blindness-related diseases. The company’s therapy utilizes advanced technology to deliver a light-sensor gene directly to cone cells that have lost their light sensitivity. By repairing these cells' ability to detect light, Rhygaze seeks to enable effective vision restoration for patients. Through its specialized approach, the company aims to make significant contributions to the healthcare industry and improve the quality of life for those facing vision loss.

Tenvie Therapeutics is a biotechnology company founded to improve patients' lives with neurological, cardiometabolic, and ophthalmic diseases. The company is focused on developing small molecules targeting brain inflammation, metabolic dysfunction, and lysosomal issues, with a robust pipeline inherited from Denali Therapeutics. Tenvie is progressing a range of therapeutics aimed at addressing neurological, cardiometabolic, and ophthalmic conditions. Its collection of fully owned, highly brain-penetrant, and precisely designed peripherally restricted small molecules targets three main factors of disease: alleviating inflammation, correcting metabolic dysfunction, and rejuvenating lysosomal function.

City Therapeutics is a biopharmaceutical company specializing in the development of next-generation small-interfering RNAs (siRNAs) to enhance RNA interference (RNAi) therapies. The company's pipeline comprises innovative RNAi therapeutics targeting diverse disease indications. City Therapeutics aims to improve and expand RNAi technology to achieve better patient outcomes, led by a team of experienced scientists and industry professionals committed to advancing the field of RNA interference.

Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Moleculent is a biotechnology company focused on advancing human health through technology-enabled products that utilize insights into the molecular basis of human biology. The company is dedicated to decoding human biology and aims to significantly enhance therapies and diagnostics by leveraging new scientific knowledge. Moleculent believes that a deeper understanding of molecular mechanisms, especially in relation to health and disease, will emerge over the next decade, paving the way for innovative healthcare solutions. Through its efforts, the company seeks to provide healthcare professionals with access to molecular science-based therapies and diagnostics that can improve patient care and outcomes.

Vilya is a biotechnology company focused on developing innovative drugs that precisely target the underlying biology of diseases. By leveraging advanced computational techniques, Vilya aims to create a new class of medicines that can efficiently navigate uncharted chemical spaces and generate novel molecular structures. These structures, which are designed to possess essential drug-like properties, can range in size between small molecules and antibodies. Vilya's platform is engineered to improve the drug discovery process, enabling more effective treatments by facilitating the disruption of protein-protein interactions and ensuring optimal movement through biological membranes. Through its pioneering approach, Vilya is dedicated to advancing therapeutic options for patients.

Slingshot Biosciences, Inc. is a biotechnology company based in Emeryville, California, specializing in the development of engineered synthetic cells for diagnostics and therapeutics. Founded in 2012, the company operates within the industrial synthetic biology sector, focusing on delivering innovative solutions that address challenges in research and development. Slingshot Biosciences aims to provide cost-effective and straightforward approaches to enhance drug research by enabling precise measurement and standardization in cell analysis. Their technology eliminates the need for cold-chain storage, facilitating access to advanced diagnostics and therapeutics, particularly for neglected and rare diseases.

Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of treatment options, including both oral and injectable therapies, specifically targeting incretin, non-incretin, and combination approaches. By integrating proprietary health technology tools, Metsera aims to provide personalized care that meets the evolving demands of weight loss treatment. Its commitment to addressing multiple therapeutic targets positions the company to significantly impact the future of obesity management and related metabolic diseases.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative neuropsychiatric medicines for conditions with significant unmet needs. The company's approach emphasizes the creation of therapies that offer oral bioavailability, which allows for effective drug delivery while minimizing first-pass metabolism and reducing the risk of hepatotoxicity and other side effects. By addressing these critical challenges, Seaport Therapeutics aims to improve the quality of life for patients living with neuropsychiatric disorders.

Areteia Therapeutics is a biotechnology company focused on developing innovative treatments for asthma, particularly eosinophilic asthma. Spun out from Knopp in Pennsylvania, the company aims to empower asthma patients by providing them with better control over their condition. Areteia is advancing an oral drug candidate that works by inhibiting the maturation of eosinophils, which are immune cells that can damage the airways and exacerbate asthma symptoms. The drug has shown promise in clinical trials, with results indicating its potential to reduce blood eosinophil counts, a key marker associated with improved lung function. This breakthrough could offer a much-needed accessible treatment option for millions of individuals suffering from this severe form of asthma, allowing them to manage their disease more effectively and improve their quality of life.

Basking Biosciences is a startup focused on developing innovative therapies for ischemic stroke. The company is creating a reversible thrombolytic therapy aimed at restoring blood flow to the brain during such events, which can help prevent hemorrhage and minimize long-term damage. Their platform features a paired therapy that combines an active agent targeting a critical component of clot stability with a designed reversal agent. This reversal agent can be administered if bleeding occurs, neutralizing the active compound and restoring normal clotting ability. This dual approach enables healthcare professionals to provide effective treatment for acute ischemic stroke patients.

Accompany Health is a health technology company dedicated to providing comprehensive in-home care to patients, particularly in underserved regions. The organization focuses on delivering primary care services, including chronic illness management and treatment for new symptoms. By facilitating the organization and coordination of care, Accompany Health aims to alleviate the common challenges faced by patients, such as long wait times and complex healthcare navigation. The company emphasizes building long-term relationships with the individuals they serve, ensuring that patients receive continuous support and care around the clock. Their approach prioritizes dignity and accessibility, catering especially to low-income patients with complex healthcare needs through both at-home and virtual care solutions.

Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company specializes in creating a profiling and engineering technology platform that leverages advanced artificial intelligence predictions to offer a comprehensive view of the epigenome in both health and disease states. This innovative approach aims to revolutionize therapy discovery and development, enabling healthcare providers to reprogram cells back to their healthy state.

Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.

Gate Bioscience is a biotechnology company focused on developing small molecule drugs aimed at treating challenging diseases by selectively eliminating harmful extracellular proteins at their source within cells. The company utilizes a unique library of molecular gates along with specialized secretion-focused assays and technologies, leveraging its deep understanding of the biology of the secretory pathway. This approach facilitates precise, rapid, and repeatable drug discovery, allowing for the potential to address a diverse array of diseases using a single therapeutic mechanism.

Magnet Biomedicine is a biotechnology research platform focused on the discovery of molecular glues that enhance therapeutic effectiveness. Utilizing its TrueGlue discovery platform, the company employs advancements in human biology and proteomics to identify specialized adhesives that improve selectivity and foster biological synergy on specific targets. This innovative approach aims to tackle previously challenging-to-target proteins across various disease areas, including cancer, cardiovascular disease, and immune disorders. By harnessing the untapped potential of molecular glues, Magnet Biomedicine seeks to provide significant benefits in addressing complex biological mechanisms and improving treatment outcomes.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Bitterroot Bio is a biotechnology company focused on developing innovative therapies for cardiovascular disease by harnessing the immune system's natural capabilities. The company conducts research to uncover the essential roles of immune cells and immune modulators in the onset and progression of cardiovascular conditions. By leveraging immunotherapy, Bitterroot Bio aims to create and deliver novel medicines that can significantly improve treatment options for patients suffering from these diseases, thereby transforming the landscape of cardiovascular care.

Myeloid Therapeutics is an immunology company dedicated to leveraging innovative technologies to harness the potential of myeloid cells for the treatment of cancer and other diseases. The company has developed the ATAK platform, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. Initially, Myeloid Therapeutics is advancing a cell therapy program aimed at treating T cell lymphoma, as well as a primed monocyte strategy for glioblastoma. The versatility of the ATAK platform allows for scalability across various treatment modalities and disease areas, facilitating collaboration with partners to expand its applications in the field of immunotherapy.

Orbital Therapeutics is a biotechnology company dedicated to advancing global health through innovative RNA-based medicines. It develops a proprietary platform that combines cutting-edge RNA technology, delivery techniques, data analytics, and automation to create an extensive portfolio of transformative therapies across various disease areas such as vaccines, immunomodulation, protein replacement, and regenerative medicine. The company's mission is to provide patients with novel treatment options for diseases previously considered untreatable or challenging to manage.

Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing precision medicines for neurological disorders. The company focuses on creating transformational small-molecule therapies aimed at patients with central nervous system conditions. Leveraging foundational research in neuronal receptor biology, Rapport Therapeutics maps and targets specific neuronal receptor complexes, which are complex assemblies of proteins that include principal receptor subunits and receptor-associated proteins. These receptor-associated proteins are essential for regulating receptor expression and functionality, allowing the company to innovate in the treatment of neurological diseases.

Paratus Sciences is a biotechnology company focused on enhancing human health and health security through the study of bat biology. By investigating the unique characteristics of the bat genome, the company aims to identify and develop therapeutics for various diseases. Leveraging insights gained from bat biology, Paratus Sciences seeks to enable patients to combat and potentially cure the diseases they face. Through its innovative approach, the company aspires to contribute significantly to advancements in medical treatments and public health.

Aera Therapeutics is a biotechnology company focused on advancing genetic medicines through its proprietary protein nanoparticle (PNP) delivery platform. This innovative platform utilizes endogenous human proteins derived from retroelements, which self-assemble into capsid-like structures capable of packaging and transferring nucleic acid cargo. By addressing the limitations of current delivery technologies, Aera aims to enhance the efficacy and reach of genetic therapies across various tissues and disease areas. Additionally, the company holds a licensed technology that features a therapeutic enzyme platform based on novel, compact, and programmable gene-editing enzymes, further expanding its capabilities in the field of genetic medicine.

Slingshot Biosciences, Inc. is a biotechnology company based in Emeryville, California, specializing in the development of engineered synthetic cells for diagnostics and therapeutics. Founded in 2012, the company operates within the industrial synthetic biology sector, focusing on delivering innovative solutions that address challenges in research and development. Slingshot Biosciences aims to provide cost-effective and straightforward approaches to enhance drug research by enabling precise measurement and standardization in cell analysis. Their technology eliminates the need for cold-chain storage, facilitating access to advanced diagnostics and therapeutics, particularly for neglected and rare diseases.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Protillion Biosciences is a biotechnology company focused on transforming therapeutic antibody and drug discovery through its innovative protein engineering platform. This high-throughput platform is designed to streamline and enhance traditional methods of designing and developing protein-based drugs. By utilizing advanced techniques, Protillion aims to accelerate the research and development process for biologics, thereby enabling healthcare professionals to discover and bring new protein therapeutics to market more efficiently. The company's commitment to developing disruptive technology positions it as a key player in the evolving landscape of drug discovery and development.

SonoThera is a biotechnology company focused on developing innovative genetic therapies using ultrasound technology. The company's mission is to create non-viral genetic medicines that address the root causes of human diseases. SonoThera specializes in ultrasound-guided nonviral gene therapy, aiming to provide effective treatments for conditions that currently have suboptimal or no available treatments. By leveraging this approach, SonoThera seeks to enhance the health and quality of life for millions of people worldwide.

Human Immunology Biosciences is a biotechnology company dedicated to developing precision therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company is known for its lead product, felzartamab, a fully human anti-CD38 monoclonal antibody that targets and depletes CD38+ cells, including plasma and natural killer cells. This mechanism has shown promise in improving clinical outcomes across a range of immune-mediated disorders. By focusing on transformative biotechnology-based treatments, Human Immunology Biosciences aims to enhance the quality of life for patients suffering from these challenging conditions.

Treeline Biosciences is a biotechnology company founded in 2021 and based in Stamford, Connecticut. It focuses on developing transformative precision medicines aimed at treating cancer and other serious health conditions. The company employs a comprehensive drug discovery platform that integrates mechanistic biology, medicinal chemistry, computational science, structural biology, and protein science. This multidisciplinary approach is designed to support the development of innovative therapies that can significantly improve patient outcomes in oncology and beyond.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to address the underlying causes of mitochondrial dysfunction through a thorough understanding of mitochondrial mechanisms. By creating innovative treatments, Pretzel Therapeutics seeks to provide effective solutions for a range of diseases, particularly those related to aging. The company is dedicated to advancing the field of mitochondrial medicine and improving patient outcomes through targeted therapeutic approaches.

Vilya is a biotechnology company focused on developing innovative drugs that precisely target the underlying biology of diseases. By leveraging advanced computational techniques, Vilya aims to create a new class of medicines that can efficiently navigate uncharted chemical spaces and generate novel molecular structures. These structures, which are designed to possess essential drug-like properties, can range in size between small molecules and antibodies. Vilya's platform is engineered to improve the drug discovery process, enabling more effective treatments by facilitating the disruption of protein-protein interactions and ensuring optimal movement through biological membranes. Through its pioneering approach, Vilya is dedicated to advancing therapeutic options for patients.

Happy Health is a mission-driven technology company committed to transforming mental health awareness through the Happy Ring, the first wearable designed to measure your stress and mood 24/7.

Areteia Therapeutics is a biotechnology company focused on developing innovative treatments for asthma, particularly eosinophilic asthma. Spun out from Knopp in Pennsylvania, the company aims to empower asthma patients by providing them with better control over their condition. Areteia is advancing an oral drug candidate that works by inhibiting the maturation of eosinophils, which are immune cells that can damage the airways and exacerbate asthma symptoms. The drug has shown promise in clinical trials, with results indicating its potential to reduce blood eosinophil counts, a key marker associated with improved lung function. This breakthrough could offer a much-needed accessible treatment option for millions of individuals suffering from this severe form of asthma, allowing them to manage their disease more effectively and improve their quality of life.

Pheast Therapeutics is a cancer immunotherapy company established in 2020 and based in Palo Alto, California. The company is dedicated to developing innovative checkpoint therapies aimed at utilizing the innate immune system to combat cancer. Specifically, Pheast Therapeutics focuses on blocking macrophage checkpoints, which enhances the ability of macrophages to effectively eliminate tumors, particularly in ovarian and breast cancers. By targeting these immune checkpoints, Pheast Therapeutics aims to improve patient survival rates in oncology.

Proof Diagnostics is a life sciences company focused on developing diagnostic tools and therapeutic applications. The company specializes in creating rapid diagnostic tests for infectious diseases, including a critical test for the detection of coronavirus infection. With a commitment to enhancing patient care, Proof Diagnostics designs and manufactures diagnostic kits that empower medical professionals to accurately and efficiently test patients for various infections. Additionally, the company is working on a smart, portable system aimed at expanding the capabilities of disease detection.

Mozart Therapeutics is a biotechnology startup dedicated to developing innovative therapies for autoimmune and inflammatory diseases. The company specializes in creating disease-modifying CD8 T cell modulators, leveraging a unique regulatory CD8 T cell network to target a specific subset of T lymphocytes. These modulators aim to restore immune balance and mitigate the damage caused by autoreactive and pathogenic immune responses. By focusing on first-in-class CD8 Treg modulators, Mozart Therapeutics seeks to delay the onset and improve the management of various autoimmune disorders, thereby providing healthcare professionals with advanced treatment options for their patients.

Recuro Health is a developer of an integrated digital health platform that aims to transform the U.S. healthcare system from a reactive, disease-focused model to one centered on population health and outcomes. The company provides a tailored Digital Medical Home that caters to specific healthcare needs, offering essential virtual care services, including primary care, behavioral health, and urgent care. By equipping employers, providers, and managed care organizations with various digital tools, education, and guidance, Recuro Health enables patients to actively engage in their healthcare through health assessments and interactive communication with professionals, whether via messaging or video. This approach seeks to enhance patient involvement and improve health outcomes across diverse settings.

Slingshot Biosciences, Inc. is a biotechnology company based in Emeryville, California, specializing in the development of engineered synthetic cells for diagnostics and therapeutics. Founded in 2012, the company operates within the industrial synthetic biology sector, focusing on delivering innovative solutions that address challenges in research and development. Slingshot Biosciences aims to provide cost-effective and straightforward approaches to enhance drug research by enabling precise measurement and standardization in cell analysis. Their technology eliminates the need for cold-chain storage, facilitating access to advanced diagnostics and therapeutics, particularly for neglected and rare diseases.

ImmuneID is a precision immunology company that specializes in identifying and therapeutically targeting antibody interactions responsible for immune diseases. Utilizing a proprietary platform, it employs massively parallel, multiplexed, and unbiased systems to analyze millions of these interactions. This innovative approach allows researchers to observe human immune responses throughout the progression of various diseases, including autoimmunity, severe allergies, oncology, and infectious diseases. By focusing on the intricate dynamics of the immune system, ImmuneID aims to develop more effective therapeutics that can improve patient outcomes in these challenging areas of health.

Interline Therapeutics is a drug discovery company based in South San Francisco, California, founded in 2020 by Zach Sweeney. The company specializes in mapping and correcting dysfunctional protein communities to address molecular mechanisms of disease. By utilizing advancements in genomics, proteomics, structural biology, and computational chemistry, Interline has developed a precision medicine platform that focuses on three key areas: genomics, communities, and modulators. This approach enables the identification of new medicines targeting genetically validated signaling pathways, ensuring that drug candidates effectively correct dysfunctional disease networks. Through collaborations with leading academic groups, Interline aims to enhance its capabilities in drug discovery and development.

Treeline Biosciences is a biotechnology company founded in 2021 and based in Stamford, Connecticut. It focuses on developing transformative precision medicines aimed at treating cancer and other serious health conditions. The company employs a comprehensive drug discovery platform that integrates mechanistic biology, medicinal chemistry, computational science, structural biology, and protein science. This multidisciplinary approach is designed to support the development of innovative therapies that can significantly improve patient outcomes in oncology and beyond.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company is dedicated to the development and commercialization of gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company's mission is to advance these therapeutics into safe and effective treatments, significantly improving the lives of individuals affected by viral infections globally.

Altos Labs is a biotechnology company dedicated to cellular rejuvenation programming aimed at restoring cell health and resilience. The organization seeks to develop innovative approaches to medicine that can reverse diseases, injuries, and disabilities. By uniting a community of prominent scientists, clinicians, and industry leaders, Altos Labs fosters collaboration across its operations in the San Francisco Bay Area, San Diego, and Cambridge, UK, while also engaging in significant partnerships in Japan. Through its research and initiatives, the company aspires to transform the landscape of medical treatment.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies aimed at reprogramming ribonucleic acid (RNA) processing to treat various diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary biology platform to discover and develop RNA processing modulators that target previously undruggable disease drivers. Through its REMseq platform, Remix Therapeutics validates therapeutic targets and optimizes chemical compounds, facilitating the identification of patterns in RNA processing. This approach allows for the modulation of gene expression, enabling healthcare practitioners to address the underlying causes of diseases by correcting, enhancing, or eliminating gene messages at their source.

SciNeuro Pharmaceuticals is a biotechnology company based in Shanghai, China, focused on developing innovative medicines for patients with central nervous system (CNS) diseases. The company is committed to transforming the treatment landscape for these conditions through a robust product pipeline that emphasizes internal innovation and global collaboration. SciNeuro's drug development is guided by breakthrough scientific evidence, including insights from human genetics and pharmacology, targeting the underlying mechanisms of CNS diseases. By addressing these pathological mechanisms, SciNeuro aims to provide transformative therapies that not only aim to cure these diseases but also enhance the quality of life for patients.

Walden Biosciences, Inc. is a biotechnology company dedicated to developing innovative treatments for individuals suffering from kidney diseases, including chronic kidney disease and acute kidney injury. Founded in 2013 and based in Cambridge, Massachusetts, the company focuses on targeting specific biological mechanisms related to renal health. It specializes in therapies that address suPAR, an inflammatory biomarker linked to kidney function, and Dynamin, an enzyme crucial for maintaining podocyte integrity. By applying a systems-based approach, Walden Biosciences aims to transform the therapeutic landscape for kidney disease, offering targeted treatment options that address both rare and prevalent conditions affecting kidney health.

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Woodstock, Georgia, focused on developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, dermatology, animal health, eye care, and oral care. With over 100 products commercialized in 33 countries, Sonoma addresses unmet medical needs through its innovative therapies aimed at chronic skin conditions. Key offerings include Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription product for dermatoses; Celacyn gel for scar management; and SebuDerm for seborrheic dermatitis. Additionally, the company provides Microcyn, which targets various pathogens to promote wound healing, and Acuicyn, designed for eye care. Sonoma Pharmaceuticals was formerly known as Oculus Innovative Sciences, Inc. and has been incorporated since 1999. Its commitment to improving patient care and reducing healthcare costs is reflected in its diverse product portfolio that caters to both prescription and non-prescription needs.

Sonoma Biotherapeutics, Inc. is focused on developing adoptive T regulatory (Treg) cell therapies aimed at treating autoimmune and degenerative diseases. Established in 2019 and based in South San Francisco, California, with an additional office in Seattle, the company employs next-generation genome editing and target-specific cell therapy techniques to innovate in the field of Treg cell therapeutics. The firm aims to create disease-modifying and potentially curative therapies that promote self-tolerance and inhibit harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded by experts in Treg biology and cell therapy, Sonoma Biotherapeutics integrates advanced methodologies to enhance its therapeutic offerings.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Bit.bio is a synthetic biology company focused on revolutionizing the production and utilization of consistent and functional human cells. Their mission is to enhance health outcomes by applying computational principles to biological processes, specifically through their patented opti-ox™ technology. This innovative approach allows for the reprogramming of human induced pluripotent stem cells into precise and mature cell types. By providing scalable and reliable batches of human cells, Bit.bio aims to improve research, facilitate drug discovery, and foster the development of advanced cell and tissue therapies. The company has assembled a team of experts in stem cells, cellular reprogramming, and mathematical modeling, emphasizing collaboration and ambition to drive their goals forward. Through their efforts, Bit.bio seeks to democratize access to vital cellular resources, ultimately transforming the landscape of medicine.

Verve Therapeutics is a genetic medicines company based in Cambridge, Massachusetts, focused on innovative therapies for cardiovascular disease. Founded in 2018, the company aims to transform the management of cardiovascular conditions from chronic treatments to single-course gene editing medicines. Verve Therapeutics employs advanced gene-editing technology and human genetic analysis to develop targeted therapies that reduce the risk of coronary artery diseases. Its initial programs focus on the PCSK9 and ANGPTL3 genes, which are crucial for lowering harmful blood lipids like low-density lipoprotein cholesterol. The company collaborates with strategic partners, including Beam Therapeutics for delivery technologies and Verily for gene editing delivery vehicles, enhancing its capabilities in the biotechnology and healthcare sectors.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company specializes in induced pluripotent stem cells (iPSCs) to create patient-specific cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By combining genomic approaches with stem cell biology, Aspen Neuroscience aims to address significant unmet medical needs and modify the progression of Parkinson's disease through personalized and restorative treatments.

CERo Therapeutics, Inc. is a biotechnology company based in San Francisco, California, focused on researching and developing cellular immunotherapy platforms. Established in 2016, the company specializes in advancing next-generation engineered T-cell therapeutics aimed at treating cancer. CERo Therapeutics employs a proprietary approach to T cell engineering that combines elements of both innate and adaptive immunity, creating a hybrid platform designed to engage the body’s comprehensive immune response. This innovative strategy seeks to optimize cancer therapy by effectively harnessing the full potential of the immune system to eliminate disease.

Sonoma Biotherapeutics, Inc. is focused on developing adoptive T regulatory (Treg) cell therapies aimed at treating autoimmune and degenerative diseases. Established in 2019 and based in South San Francisco, California, with an additional office in Seattle, the company employs next-generation genome editing and target-specific cell therapy techniques to innovate in the field of Treg cell therapeutics. The firm aims to create disease-modifying and potentially curative therapies that promote self-tolerance and inhibit harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded by experts in Treg biology and cell therapy, Sonoma Biotherapeutics integrates advanced methodologies to enhance its therapeutic offerings.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

Epirium Bio, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing therapeutics for cardiovascular diseases, metabolic syndrome, and disorders characterized by mitochondrial dysfunction. Founded in 2008, the company leverages unique insights into mitochondrial biology and tissue regeneration to create a small molecule platform aimed at improving muscle strength and facilitating tissue regeneration. Epirium Bio's innovative approach addresses significant clinical needs in treating neuromuscular, neurodegenerative, and mitochondrial disorders, enabling healthcare providers to better support patients suffering from conditions such as muscular dystrophy.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.

Boundless Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, focused on developing innovative therapies for the treatment of aggressive cancers. The company specializes in targeting extrachromosomal DNA (ecDNA), a key factor in the amplification of oncogenes that affects over 14% of cancer patients. By investigating the biology of ecDNA, Boundless Bio aims to create transformative treatments for previously untreatable cancers. Its lead therapeutic candidate, BBI-355, is an oral selective inhibitor of checkpoint kinase 1 (CHK1) designed to manage the replication and transcription of ecDNA in cancer cells. Founded in 2018, Boundless Bio is committed to addressing the significant unmet medical needs of patients with oncogene amplified tumors.

One BioMed is a molecular life science company focused on advancing human health through innovative biomedical research, products, and testing solutions. The company specializes in developing a diagnostics testing platform that facilitates the purification and isolation of nucleic acids from diverse samples. Its offerings include DNA and RNA cartridge kits, which are integral to its platform that integrates molecular diagnostic tools. Utilizing proprietary silicon biophotonics sensing technology, One BioMed enables healthcare professionals to detect point-of-care infectious diseases efficiently and effectively. Through its commitment to innovation, the company aims to enhance diagnostic capabilities in the medical field.

Locanabio, Inc., based in San Diego, California, is a biotechnology company specializing in RNA-targeted gene therapies. Founded in 2016, the company focuses on developing treatments for severe neurodegenerative, neuromuscular, and retinal diseases. Locanabio's platform is designed to modify disease-causing RNA, offering therapeutic candidates distinct from traditional DNA-targeted approaches. The company aims to address a spectrum of underserved diseases, including those affecting the nervous system, muscles, and eyes.

Verve Therapeutics is a genetic medicines company based in Cambridge, Massachusetts, focused on innovative therapies for cardiovascular disease. Founded in 2018, the company aims to transform the management of cardiovascular conditions from chronic treatments to single-course gene editing medicines. Verve Therapeutics employs advanced gene-editing technology and human genetic analysis to develop targeted therapies that reduce the risk of coronary artery diseases. Its initial programs focus on the PCSK9 and ANGPTL3 genes, which are crucial for lowering harmful blood lipids like low-density lipoprotein cholesterol. The company collaborates with strategic partners, including Beam Therapeutics for delivery technologies and Verily for gene editing delivery vehicles, enhancing its capabilities in the biotechnology and healthcare sectors.

Erasca, Inc. is a clinical-stage precision oncology company based in San Diego, California, focused on discovering and developing therapies for patients with cancers driven by the RAS/MAPK pathway. Founded in 2018, the company employs an artificial intelligence drug discovery platform known as OPRA, which utilizes machine learning to analyze large-scale data sets and identify novel tumor biology, thereby accelerating drug development. Erasca is developing a pipeline of oncology drugs, including Naporafenib, an innovative pan-RAF inhibitor aimed at treating NRAS-mutant melanoma and other RAS/MAPK-driven tumors. Additionally, the company is advancing ERAS-007, an oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor, targeting key nodes in the RAS/MAPK signaling pathway. Through its research and collaborations, Erasca aims to provide precision oncology options that offer potential solutions for treating and possibly curing cancer.

Maze Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, established in 2017. The company specializes in developing genetic modifier therapeutics aimed at addressing unmet medical needs. Utilizing its innovative Compass platform, Maze Therapeutics focuses on identifying rare genetic variants that offer protective effects against diseases. By analyzing large-scale human genetic data and employing functional genomics, the company maps these variants to the biological pathways that contribute to specific conditions in patient populations. This approach enables a deeper understanding of target biology and facilitates the development of novel therapies, positioning Maze Therapeutics as a key player in translating genetic insights into effective medicines.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York. It focuses on developing innovative therapeutics aimed at preventing cancer relapse and metastasis, which are significant contributors to cancer-related mortality. The company’s therapeutic pipeline addresses mechanisms of treatment resistance and utilizes advanced technologies, including artificial intelligence and machine learning, to analyze multi-omic and phenotypic profiles of tumors. This approach aims to generate insights that link tumor characteristics to clinical outcomes, ultimately striving to improve patient survival and quality of life by enabling longer, cancer-free lives.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

Lyell Immunopharma Inc is a clinical-stage cell therapy company focused on developing innovative treatments for patients with solid tumors through T cell reprogramming. The company aims to overcome significant challenges in adoptive T cell therapy, specifically T cell exhaustion and loss of durable stemness, which impede effective and lasting responses in cancer treatment. Utilizing its proprietary platforms, Gen-R and Epi-R, Lyell is working to enhance the proliferative capacity, self-renewal, and differentiation abilities of T cells. The company's product pipeline includes several candidates, such as LYL797, LYL119, and LYL845, all designed to deliver improved and potentially curative outcomes for patients suffering from solid tumors.

Glympse Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing modular nanoparticle sensors for noninvasive diagnostics. Founded in 2015, the company focuses on creating diagnostic solutions for various diseases, including fibrosis, cancer, immunology, and infectious diseases. Utilizing a unique platform technology originally developed at MIT, Glympse Bio employs precisely engineered diagnostic agents that interrogate the body to detect specific disease states and transmit this information to urine for analysis. This innovative approach facilitates predictive monitoring and enhances the ability of physicians to assess treatment responses accurately. The company aims to transform disease monitoring and improve patient outcomes through its Glympse Inside product engine, which supports comprehensive, pan-disease diagnostics.

Magnolia Neurosciences Corporation is a New York-based company focused on drug discovery and development, specifically targeting neuroprotective therapies for central nervous system diseases and neurodegeneration. Established in 2018, the company aims to create proprietary small molecule therapeutics that prevent neuronal cell death, offering new treatment options for patients with neurodegenerative disorders and related conditions. Magnolia Neurosciences was founded to advance technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium. Through its innovative approach, the company seeks to address significant medical needs in the field of neurology.

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, that specializes in developing innovative therapies for neuropsychiatric disorders and pain management. The company is advancing its lead product candidate, KarXT, an oral modulator that has completed a Phase II clinical trial for acute psychosis in schizophrenia and is undergoing Phase Ib trials for various central nervous system disorders, including the cognitive and negative symptoms associated with schizophrenia, Alzheimer's disease, and dementia-related psychosis. Karuna Therapeutics is also actively developing a pipeline of muscarinic-targeted drug candidates to address unmet medical needs in these challenging areas. Founded in 2009, the company has established partnerships and licensing agreements to support its drug discovery efforts and to enhance its research capabilities.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Insitro, Inc. is a data-driven company focused on drug discovery and development, particularly targeting nonalcoholic steatohepatitis (NASH). Founded in 2018 by Daphne Koller and based in South San Francisco, California, Insitro harnesses machine learning and high-throughput biology to revolutionize the process of drug discovery. The company creates extensive functional genomic data sets and integrates them with patient data through innovative machine learning techniques. This approach allows Insitro to build predictive models that enhance target selection, streamline the design of therapeutics, and optimize drug development strategies. By addressing critical challenges in pharmaceutical research and development, Insitro aims to accelerate the delivery of new and effective treatments to patients.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Rodeo Therapeutics Corp. is a Seattle-based drug development company that focuses on creating novel small molecule therapies aimed at tissue repair and regeneration. Founded in 2017, the company targets specific biological pathways and enzyme mechanisms critical for healing. Its primary objectives include developing treatments for inflammatory bowel disease and enhancing blood cell reconstitution after bone marrow transplants. Rodeo's innovative approach involves increasing tissue levels of prostaglandin PGE2 by inhibiting the enzyme 15-PGDH, which has shown promise in protecting against colitis and promoting liver regeneration in various animal models. This research positions Rodeo Therapeutics to contribute significantly to the medical management of these conditions.

Mindstrong Health, established in 2013 and based in Mountain View, California, specializes in remote mental health care. It offers a digital therapeutic platform that combines AI-powered technology, data, and clinical expertise to monitor and improve users' mental health. The platform tracks symptoms continuously through passive data collection from human-computer interactions, enabling evidence-based interventions and personalized support. Services include cognitive behavioral therapy, psychoeducation, crisis management, and more, helping thousands of users, including those with serious mental illness.

Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

Bio Palette is a company focused on advancing gene-editing techniques and developing therapies through innovative technology. The firm operates a platform that combines genome editing with microbiome engineering, allowing for the cultivation of bacteria tailored through genetic modifications. This approach enables researchers to explore and test the potential of gene editing in various applications. Bio Palette categorizes its business development into three fields based on the types of cells targeted for genome editing, positioning itself at the forefront of biotechnology and therapeutic innovation.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Boragen Inc. is a biotechnology company based in Durham, North Carolina, founded in 2015. It specializes in the design and development of multifunctional small molecule boron solutions for applications in crop protection, animal health, and human health. Boragen's innovative synthetic chemistry platform enables the production of next-generation fungicides, including BAG8, a multisite fungicide, and BN2266, which targets mRNA processing. The company is also developing a dual function nematicide-fungicide for root protection and endo-parasiticides that can overcome resistance. By leveraging the unique properties of boron, Boragen aims to create sustainable agricultural solutions that reduce the probability of fungicide resistance and minimize chemical usage while maintaining efficacy across various sectors.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative therapeutics to address significant unmet medical needs. Established in 2013, Vividion utilizes a pioneering platform for proteome-wide small molecule drug discovery, which combines advanced synthetic chemistry techniques with chemical proteomics. This approach allows the company to expand the druggable proteome and target challenging proteins, ultimately enabling the discovery of transformative treatments for serious illnesses. Vividion's scientific foundation stems from experts in chemical biology and synthetic chemistry at The Scripps Research Institute, reflecting its commitment to advancing therapeutics that can significantly improve patient outcomes.

ApoGen Biotechnologies, Inc. is a biotechnology company based in Seattle, Washington, established in 2014. The company specializes in developing innovative therapeutics aimed at addressing the challenges of drug resistance in cancer treatment. Recognizing that the mutation of cellular DNA is central to cancer progression, ApoGen focuses on therapies that target key drivers of genomic mutations and tumor evolution. By doing so, the company aims to slow or halt the ongoing mutations within cancer genomes, which are significant contributors to treatment failure, cancer recurrence, and metastasis. Through its advanced therapeutic approaches, ApoGen Biotechnologies seeks to improve outcomes for patients facing the complexities of cancer evolution and drug resistance.

Nohla Therapeutics, Inc., established in 2015 and headquartered in Seattle, Washington, specializes in developing and manufacturing ex vivo expanded universal donor cellular therapies. The company's core technology enables the expansion of key cancer-fighting cells from umbilical cord blood, eliminating the need for HLA matching. Nohla offers programs such as Natural Killer (NK) cell therapy and Dilanubicel, a universal donor hematopoietic stem and progenitor cell product used for treating chemotherapy-induced neutropenia and other indications. Its products are manufactured and cryopreserved in advance, ensuring immediate availability for patient treatment.

Genomics Medicine Ireland is an Irish life sciences company conducting a substantial research study across Ireland. Its primary focus is to investigate the human genome, aiming to understand the relationship between genetics, health, and disease.

Blackthorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, founded in 2013. The company focuses on developing precision medicine for neurobehavioral disorders, utilizing advances in computational and clinical neuroscience. By leveraging its proprietary computational platform, Blackthorn aims to address historical challenges in drug discovery by targeting dysfunctional brain circuits. This approach enables the identification of novel drug candidates and biologically-based patient subgroups that are most likely to respond to specific treatments. Through its innovative strategies, Blackthorn seeks to enhance the precision of therapeutic interventions for disorders of the central nervous system, ultimately improving patient outcomes.

Carrick Therapeutics, Ltd. is a Dublin-based company founded in 2015 that specializes in the development of innovative cancer therapeutics. The company focuses on targeting molecular pathways associated with aggressive and resistant forms of cancer. By employing advanced mechanisms, Carrick Therapeutics aims to transform cancer treatment and improve patient outcomes. Their approach facilitates the early detection of predictive biomarkers, allowing for timely initiation of personalized treatments.

Just Evotec Biologics, founded in 2014 and acquired by Evotec in 2019, specializes in the development of biotherapeutic technologies aimed at expanding global access to these treatments. The company leverages its expertise in antibody discovery, molecular design, and manufacturing processes to create innovative solutions that accelerate the development of biotherapeutics while significantly lowering manufacturing costs. Utilizing machine learning-driven technologies, Just Evotec Biologics provides clients with integrated designs that streamline the entire process from development to production, ensuring efficient and effective delivery of biologic therapies.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company based in Hangzhou, China, that specializes in the development of antibody and recombinant protein biotherapeutics. Founded in 2016, the company focuses on leveraging its expertise in molecular design, process design, and drug product design to facilitate the development of biologics. By employing advanced protein, process, and manufacturing sciences, Hangzhou Just Biotherapeutics aims to overcome technical challenges associated with protein therapeutics, thereby accelerating development timelines and significantly lowering manufacturing costs. As a subsidiary of MabSpace Biosciences Co., Ltd., the company positions itself as a key player in the biopharmaceutical sector, dedicated to enhancing the efficiency of biomedical innovation.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies for dermatological conditions. The company focuses on immunology and inflammation, targeting specific pathways in the skin. Its lead product candidates include SNA-120, a first-in-class inhibitor currently undergoing Phase IIb clinical trials for psoriasis and associated itching, and SNA-125, a dual Janus kinase 3 inhibitor in Phase I/II trials aimed at treating atopic dermatitis and psoriasis. Additionally, Sienna is developing SNA-001, a topical silver particle suspension in pivotal trials for acne treatment and the reduction of light-pigmented hair. Founded in 2010 and headquartered in Westlake Village, California, Sienna Biopharmaceuticals has experienced significant operational challenges, filing for Chapter 11 bankruptcy in 2019, which was later converted to Chapter 7. The company, previously known as Sienna Labs, Inc., rebranded in February 2016 to better reflect its focus on dermatology and aesthetics.

OncoResponse Inc. is an immuno-oncology biotechnology company based in Houston, Texas, focused on developing innovative cancer therapies. The company utilizes a proprietary human antibody platform to identify fully human monoclonal antibodies targeting immuno-oncology pathways. By probing the adaptive immune systems of cancer patients who have shown exceptional responses to checkpoint inhibitors, OncoResponse aims to discover novel therapeutic antibodies. Its research emphasizes addressing immunosuppressive myeloid biology and enhancing immune activation, with the goal of transforming cold tumors into hot tumors that are more responsive to treatment. Through its advanced antibody pipeline, OncoResponse is dedicated to providing effective solutions for cancer treatment.

Homology Medicines, Inc., established in 2015 and headquartered in Bedford, Massachusetts, is a biotechnology company focused on developing genetic medicines for patients with rare genetic diseases. The company's proprietary platform employs human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies or nuclease-free gene editing treatments in vivo, targeting various disease-relevant tissues such as the liver, central nervous system, and eye. Homology Medicines has two lead product candidates: HMI-102, currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, and HMI-103, intended for PKU treatment in pediatric patients. Additionally, the company is developing HMI-202 to treat metachromatic leukodystrophy. Homology Medicines aims to cure the underlying causes of these diseases by leveraging its robust intellectual property portfolio and experienced management team with a proven track record in rare disease therapeutics.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies for dermatological conditions. The company focuses on immunology and inflammation, targeting specific pathways in the skin. Its lead product candidates include SNA-120, a first-in-class inhibitor currently undergoing Phase IIb clinical trials for psoriasis and associated itching, and SNA-125, a dual Janus kinase 3 inhibitor in Phase I/II trials aimed at treating atopic dermatitis and psoriasis. Additionally, Sienna is developing SNA-001, a topical silver particle suspension in pivotal trials for acne treatment and the reduction of light-pigmented hair. Founded in 2010 and headquartered in Westlake Village, California, Sienna Biopharmaceuticals has experienced significant operational challenges, filing for Chapter 11 bankruptcy in 2019, which was later converted to Chapter 7. The company, previously known as Sienna Labs, Inc., rebranded in February 2016 to better reflect its focus on dermatology and aesthetics.